Skip to main content
SpringerLink
Log in

Statins and Cholesterol: How Low Can You Go?

  • Chapter
Vascular Complications in Human Disease

  • 615 Accesses

Abstract

Current treatment guidelines1–3 recommend targets for serum/plasma low-density lipoprotein cholesterol (LDL-C) that range from 1.8 to 2.0 mmol/l. The 1.8 mmol/l goal is included in the National Cholesterol Educational Program (NCEP) Adult Treatment Panel (ATP) III guidelines (USA)1,2 as an option for very high-risk patients. The same guidelines recommend 2.6 mmol/l for highrisk patients. The December 2005 Joint British Societies’ 2 (JBS2) guidelines3 on prevention of cardiovascular disease in clinical practice recommend an LDL-C of 2.0 mmol/l for high-risk patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.

    Article  Google Scholar 

  2. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227–239.

    Article  PubMed  Google Scholar 

  3. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. 5):v1–52.

    Article  Google Scholar 

  4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.

    Article  Google Scholar 

  5. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  6. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–1435.

    Article  PubMed  CAS  Google Scholar 

  7. de Lemos JA, Blazing MA, Wiviott SD, et al. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307–1316.

    Article  PubMed  Google Scholar 

  8. Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437–2445.

    Article  PubMed  CAS  Google Scholar 

  9. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–1080.

    Article  PubMed  CAS  Google Scholar 

  10. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heartdisease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220–228.

    Article  PubMed  Google Scholar 

  11. Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipidlowering disease management clinics: the alliance study. J Am Coll Cardiol 2004;44:1772–1779.

    PubMed  Google Scholar 

  12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998–3007.

    Article  Google Scholar 

  13. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.

    Article  PubMed  CAS  Google Scholar 

  14. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999;282:2012–2018.

    Article  PubMed  CAS  Google Scholar 

  15. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540–556.

    Article  PubMed  CAS  Google Scholar 

  16. Ray KK, Cannon CP, McCabe CH, et al. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405–1410.

    Article  PubMed  CAS  Google Scholar 

  17. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005;96(5A):61F–68F.

    Article  PubMed  CAS  Google Scholar 

  18. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38.

    Article  PubMed  CAS  Google Scholar 

  19. Ray KK, Cannon CP, Cairns R, et al. PROVE IT-TIMI 22 Investigators. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1417–1424.

    Article  PubMed  CAS  Google Scholar 

  20. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–2016.

    Article  PubMed  Google Scholar 

  21. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728–734.

    Article  PubMed  CAS  Google Scholar 

  22. Shepherd J, Wenger N, for the TNT Steering Committee and Investigators. Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) Study. American College of Cardiology 2006 Scientific Sessions; March 13, 2006; Atlanta, GA. Abstract 808-803.

    Google Scholar 

  23. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Design 2003;9:2425–2443.

    Article  CAS  Google Scholar 

  24. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511–528.

    Article  PubMed  CAS  Google Scholar 

  25. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587–595.

    Article  PubMed  CAS  Google Scholar 

  26. Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005;179:361–367.

    Article  PubMed  CAS  Google Scholar 

  27. Bays HE, Ose L, Fraser N, et al. Ezetimibe Study Group. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipidaltering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004;26:1758–1773.

    Article  PubMed  CAS  Google Scholar 

  28. Ballantyne CM, Houri J, Notarbartolo A, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409–2415.

    Article  PubMed  CAS  Google Scholar 

  29. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155–168.

    Article  PubMed  CAS  Google Scholar 

  30. The UK HDL-C Consensus group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004;20:241–247.

    Article  CAS  Google Scholar 

  31. Mikhailidis DP, Wierzbicki AS. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000;16:139–146.

    Article  PubMed  CAS  Google Scholar 

  32. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81(4A):66B–69B.

    Article  PubMed  CAS  Google Scholar 

  33. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556–1565.

    Article  PubMed  CAS  Google Scholar 

  34. Blumenthal RS, Kapur NK. Can a potent statin actually regress coronary atherosclerosis? JAMA 2006;295:1583–154.

    Article  PubMed  CAS  Google Scholar 

  35. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411–146.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, Royal Free and University College Medical School, London, UK

    Dimitri P. Mikhailidis MD, FFPM, FRCP, FRCPath

Authors
  1. Dimitri P. Mikhailidis MD, FFPM, FRCP, FRCPath
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Royal Free and University College Medical School, London, UK

    David Abraham PhD (Professor of Cellular and Molecular Biology) (Professor of Cellular and Molecular Biology)

  2. Clinical Biochemistry, Royal Free and University College Hospital Medical School, London, UK

    Michael Dashwood PhD (Principal Research Fellow) (Principal Research Fellow)

  3. The National Pulmonary Hypertension Unit, Royal Free Hospital, London

    Clive Handler BSc, MD, MRCP, FACC, FESC (Consultant in Pulmonary Hypertension and Honorary Senior Lecturer) (Consultant in Pulmonary Hypertension and Honorary Senior Lecturer)

  4. Department of Medicine, Royal Free and University College Hospital Medical School, London, UK

    Clive Handler BSc, MD, MRCP, FACC, FESC (Consultant in Pulmonary Hypertension and Honorary Senior Lecturer) (Consultant in Pulmonary Hypertension and Honorary Senior Lecturer)

  5. Royal Free Hospital, London, UK

    Gerry Coghlan MD, FRCP (Consultant Cardiologist) (Consultant Cardiologist)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Mikhailidis, D.P. (2008). Statins and Cholesterol: How Low Can You Go?. In: Abraham, D., Dashwood, M., Handler, C., Coghlan, G. (eds) Vascular Complications in Human Disease. Springer, London. https://doi.org/10.1007/978-1-84628-919-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-919-4_14

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-918-7

  • Online ISBN: 978-1-84628-919-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation